Group items tagged

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

The majority of women who undergo surgery for suspected ovarian cancer do not actually have the disease, but these unnecessary surgeries could soon be reduced thanks to a novel blood test developed by a Swedish research team.

n the modern world, everything is changing substantially. Significant changes are observed in all aspects of life style, eating habits, Medicine and Technology, Health and diseases.

In the modern world, everything is changing substantially. Significant changes are observed in all aspects of life style, eating habits, Medicine and Technology, Health and diseases.

Know the whereabouts of ovarian cancer in women as Dr. Manish Singhal, the best Oncologist in Delhi-NCR, breaks down the common myths and ideologies of woman that circles around ovarian cancer.

Note that the expressions of malignancy and cancer are also used to describe cancer. The benign tumor is not cancerous, and is less health. It can put pressure on an organ or tissue, but in a limited space and does not spread in the body. Prevalence

Hi friends ,sorry for a delayed posting.Today i'll briefly review the RISK FACTORS OF BREAST CANCER.Breast cancer is a very common cancer.Breast cancer is perhaps the most common cancer in women of the developed countries.

Good morning friends.Today I'll post a brief review on the 2nd hormonal assay for pregnancy diagnosis: SERUM PROGESTERONE.Progesterone is a steroid hormone that is produced by the corpus luteum,which prepares the uterus for pregnancy.